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Abstract. 
 
Autocrine EGF-receptor (EGFR) ligands 
are normally made as membrane-anchored precursors 
that are proteolytically processed to yield mature, solu-
ble peptides. To explore the function of the membrane-
anchoring domain of EGF, we expressed artificial EGF 
genes either with or without this structure in human 
mammary epithelial cells (HMEC). These cells require 
activation of the EGFR for cell proliferation. We found 
that HMEC expressing high levels of membrane-
anchored EGF grew at a maximal rate that was not in-
creased by exogenous EGF, but could be inhibited by 
antiÐEGFR antibodies. In contrast, when cells ex-
pressed EGF lacking the membrane-anchoring domain 
(sEGF), their proliferation rate, growth at clonal densi-
ties, and receptor substrate phosphorylation were not 
affected by antiÐEGFR antibodies. The sEGF was 
found to be colocalized with the EGFR within small cy-
toplasmic vesicles. It thus appears that removal of the 
membrane-anchoring domain converts autocrine to in-
tracrine signaling. Significantly, sEGF inhibited the or-
ganization of HMEC on Matrigel, suggesting that spa-
tial restriction of EGF access to its receptor is necessary 
for organization. Our results indicate that an important 
role of the membrane-anchoring domain of EGFR 
ligands is to restrict the cellular compartments in which 
the receptor is activated.
Key words: epidermal growth factor ¥ autocrine ¥ in-
tracrine ¥ receptors ¥ epithelium
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HE
 
 epidermal growth factor receptor system is per-
haps the best characterized of all growth factor or
cytokine systems. Isolated over 35 yr ago, EGF has
been found to stimulate growth in a wide variety of epithe-
lial cell types (Carpenter and Cohen, 1990). EGF was the
first of what turned out to be a family of growth factors
that bind to the EGF receptor (EGFR).
 
1
 
 These include
TGF
 
a
 
 (Derynck, 1992), amphiregulin (Shoyab et al., 1989),
heparin binding EGF-like growth factor (HB-EGF; Hi-
gashiyama et al., 1991), betacellulin (Shing et al., 1993),
and epiregulin (Toyoda et al., 1995). All these ligands are
made as membrane-spanning prohormones that are pro-
cessed and released through regulated proteolysis (Mas-
sagu and Pandiella, 1993). Similarly, the EGF receptor is
also one member of a family that includes erbB-2, -3, and
-4 (Lupu et al., 1995). It is thought that ligand binding
to EGF receptors leads to homo- and heterodimerization
of these family members, perhaps leading to diverse re-
sponses depending on the patterns of pairings (Earp et al.,
1995; Alroy and Yarden, 1997). Whether different ligands
promote different patterns of dimerization is not certain,
although some data suggests that this may be the case
(Beerli and Hynes, 1996). What is clear, however, is that a
variety of different EGFR ligands are found throughout
adult tissues such as the gut, the kidneys, and the skin
(Fisher et al., 1989; Saeki et al., 1992; Downing et al.,
1997). Whether the different EGFR ligands play different
roles in normal tissue homeostasis is unknown.
The EGF receptor is known to play an important role
during development. Knockout of the EGFR gene results
in numerous developmental abnormalities in the brain,
skin, and gut (Miettinen et al., 1995; Sibilia and Wagner,
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1995; Threadgill et al., 1995). Interestingly, knockout of
the TGF
 
a
 
 gene results in only a mild phenotype, such as
disoriented hair follicles, indicating that either other mem-
bers of this ligand family may be more important, or there
is redundancy of ligand function (Luetteke et al., 1993;
Mann et al., 1993). It is possible that diverse functions of
the EGFR depend on structurally different ligands. It has
been shown that the postendocytic trafficking pattern of
different EGFR ligands depends on their pH-sensitive dis-
sociation from the EGFR (Ebner and Derynck, 1991;
French et al., 1995). This may control persistence of recep-
tor signaling, which, in turn, may alter the response of cells
to EGFR activation (Traverse et al., 1994). Although
there is evidence that TGF
 
a
 
 is more effective than EGF
in stimulating some cellular responses, such as migration
and angiogenesis (Schreiber et al., 1986; Barrandon and
Green, 1987), all EGFR ligands display very similar cellu-
lar and biochemical effects in vitro (Riese et al., 1996).
This suggests that, in vivo, patterns of tissue distribution or
methods of presentation may be more important than
structure in dictating biological action of the EGFR
ligands. Nevertheless, different ligand structures could po-
tentially generate different biological responses depending
on the context (Besner et al., 1992; Tzahar et al., 1997).
All the EGFR ligands consist of a conserved receptor-
binding core domain flanked on the carboxy side by a
membrane-spanning domain and on the amino side by a
highly variable extracellular extension (Massagu and Pan-
diella, 1993). These extensions can be proteolytically re-
moved before release of the ligand, such as the case with
TGF
 
a
 
 (Derynck, 1992). In other ligands, such as HB-
EGF, most of the amino terminus is retained, which allows
binding to extracellular glycosaminoglycans or to other
cell surface molecules (Thompson et al., 1994). This extra-
receptor binding can have profound effects on cell respon-
siveness in vitro and presumably in the intact animal
(Cook et al., 1995). The proteolytic release of ligands, such
as HB-EGF, can change their activity from juxtacrine to
paracrine (Goishi et al., 1995). The transmembrane and
cytoplasmic domains of the different ligands are also di-
verse, and may regulate cellular transport, localization, or
proteolytic release (Dempsey et al., 1997). Although the
membrane anchoring domain of EGFR ligands may regu-
late their cellular distribution, it remains to be demon-
strated that altered cellular distribution has an impact on
their biological activity.
Understanding the role of the membrane-anchoring do-
main of EGFR ligands is complicated by the fact that most
cells making EGFR ligands also express the EGFR. Dis-
ruption of the EGFR gene in mice has shown that epithe-
lial cells are most profoundly affected by receptor loss
(Miettinen et al., 1995; Sibilia and Wagner, 1995; Thread-
gill et al., 1995). These cells, such as those found in the gut,
the kidneys, and epidermis, have all been shown to express
one or more EGFR ligands (Fisher et al., 1989; Barnard
et al., 1994; Hashimoto et al., 1994; Sakurai et al., 1997).
Although membrane-anchored growth factors have been
shown to be biologically active in a juxtacrine fashion
(Brachmann et al., 1989; Wong et al., 1989; Anklesaria et al.,
1990; Higashiyama et al., 1995), these studies have used
experimental systems in which the cell type expressing the
ligand is distinct from the cell type expressing the receptor.
In this situation, it is relatively simple to envision how spa-
tially restricted juxtacrine signaling could play an impor-
tant role in tissue organization. If a cell expresses both a
receptor and a membrane-anchored growth factor, how-
ever, then juxtacrine signaling is unlikely to indicate cel-
lular context. In addition, membrane-anchored EGFR
ligands can be converted into soluble forms that are also
biologically active (Derynck, 1992; Massagu and Pandi-
ella, 1993). Thus, the function of the membrane-anchoring
domain in autocrine signaling is unclear.
To determine the role that ligand structure and distri-
bution play in the function of the EGFR system, we have
employed human mammary epithelial cells (HMEC;
Stampfer et al., 1997). These cells require activated EGFR
for both cell division and motility (Matthay et al., 1993;
Stampfer et al., 1993). They express a number of EGFR
ligands and can thus grow in the absence of exogenous
EGF (Li et al., 1992). Blocking the EGFR autocrine loop
by the addition of antagonistic antiÐEGFR antibodies,
however, causes the cells to enter G
 
0
 
. Removal of the anti-
bodies and addition of EGF causes the cells to synchro-
nously reenter the cell cycle (Stampfer et al., 1993). There-
fore, autocrine EGFR signaling in these cells is involved in
a variety of different functions.
To explore the role of the membrane anchoring domain
in EGFR ligand function, we constructed two derivatives
of EGF: one lacking and one possessing the natural trans-
membrane domain. These artificial ligands were then ex-
pressed in HMEC cells to determine how they affected
cell behavior. Surprisingly, we found that removal of the
transmembrane domain resulted in a noninterruptible au-
tocrine loop, apparently by an intracrine mechanism. Sig-
nificantly, these cells could not organize into complex
structures when grown on a reconstituted basement mem-
brane. Our results suggest that an important function of
the membrane-anchoring domain of EGF is to restrict the
cellular location of receptor-ligand binding.
 
Materials and Methods
 
General 
 
mAb 225 directed against the EGFR (Gill et al., 1984) was isolated from a
hybridoma cell line obtained from the American Type Culture Collection
(ATCC). Monoclonal antibody 13A9, which binds to both occupied and
empty EGFR (Winkler et al., 1989) was obtained from Genentech Inc.
(South San Francisco, CA). Monoclonal antibody HA directed against
EGF was a kind gift from Katsuzo Nishikawa of the Kanazawa Medical
University, Uchinoda, Ishikawa, Japan (Yoshitake and Nishikawa, 1988).
Recombinant EGF (QCB, Inc., Hopkinton, MA) was conjugated to key-
hole limpet hemocyanin (KLH) using sulfo-MBS (Pierce Chemical Co.,
Rockford, IL) after first introducing a sulfhydryl group using TrautÕs Re-
agent according to the manufactureÕs instruction. The KLH-EGF conju-
gate was used as an antigen to produce rabbit antisera. Polyclonal anti-
bodies against the EGFR were raised in rabbits against affinity-purified
EGFR (Gill and Weber, 1987). Vector pEGF-1 containing the mature se-
quence of human EGF was a gift from Salil Niyogi (Engler et al., 1988).
LambdaEGF116 containing the entire coding sequence for human EGF
was obtained from the ATCC. Human mammary epithelial cells 184 and
line 184A1 (substrain L5) (Stampfer et al., 1993) were obtained from Dr.
Martha Stampfer (Lawrence Berkeley Laboratories, Berkeley, CA) and
cultured in either MCDB 170 (Hammond et al., 1984) or medium DFCI-1
as described (Band and Sager, 1989). Antibodies coupled to Protein A
Sepharose beads were cross-linked to the beads using dimethyl pimelimi-
date and quenched using ethanolamine as described (Schneider et al.,
1982). Beads were washed extensively and then directly added to the cell
extracts. 
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Construction of sEGF and EGF-Ct
 
An artificial secreted form of human EGF (sEGF) was constructed using
an artificial DNA sequence derived from the amino acid sequence of ma-
ture human EGF (Engler et al., 1988) fused to a 200-bp fragment of the 5
 
9
 
untranslated region and adjacent signal sequence of the EGFR. The EGF
DNA was removed from pEGF-1 by digesting with EagI, endfilling with
Klenow, and digesting with EcoRI. The EGF DNA was ligated to pBlue-
script (Stratagene Inc., La Jolla, CA) that was digested with HindIII, end-
filled with Klenow, and digested with EcoRI to create pBluescript-EGF.
The 5
 
9
 
-untranslated region and signal sequence of the EGFR were iso-
lated by PCR with primers to the SP6 promoter (5
 
9
 
-GTA TTC TAT AGT
GTC ACC TA-3
 
9
 
) and the EGFR signal sequence (5
 
9
 
-GCC CGA CTC
GCC GGG CAG AG-3
 
9
 
) using pLOLB (Opresko and Wiley, 1990) as the
template. The PCR product was digested with XbaI to remove unwanted
vector sequences, resulting in an insert with a 5
 
9
 
 XbaI end and a single 3
 
9
 
A-overhang left by the Taq polymerase. This insert was ligated into
pBluescript-EGF that was first digested with EcoRI and endfilled with
Klenow, followed by addition of T overhangs with Taq polymerase and di-
gestion with XbaI. EGF-Ct was made by inserting the entire membrane
anchoring and cytoplasmic domain from lambdaEGF116 into pBluescript-
sEGF. Both lambdaEGF116 and pBluescript-sEGF were digested with
SphI and XhoI. After gel purification, the 760-bp fragment from pEGF
was ligated into pBluescript-sEGF. All constructs were verified by se-
quencing.
For insertion into the MFG retrovirus vector (Eming et al., 1995), StyI
and BglII sites were made at the 5
 
9
 
 and 3
 
9
 
 end of the sEGF construct using
the primers 5
 
9
 
-CTT CGG GGA GCA GCC ATG GGA CCC TCC G-3
 
9
 
and 5
 
9
 
-AGA TCT AAC GGA GCT CCC ACC ACT-3
 
9
 
. This set ampli-
fied the entire sEGF gene with the appropriate new restriction sites. The
product was then ligated into pBluescript after digestion with SmaI and
addition of T overhangs with Taq polymerase. The same protocol was fol-
lowed for the EGF-Ct construct, except that a compatible NcoI site was
used instead of the StyI site using the primer pair 5
 
9
 
-CCA TGG GAC
CCT CCG GGA CG-3
 
9
 
 and 5
 
9
 
-AGA TCT ACT GAG TCA GCT CC-3
 
9
 
.
The PCR reaction mixture included 100 pmol of each primer, 20 ng of
temple, 200 
 
m
 
M of each dNTP, 25 mM MgCl
 
2 
 
and 2.5 U of Taq polymers.
A DNA thermal cycler (Perkin Elmer Cetus Instruments, Emeryville,
CA) was used for 25 cycles with an annealing temperature at 50
 
8
 
C. Final
products were confirmed by DNA sequencing.
DNA fragments encoding sEGF or EGF-Ct were gel purified and li-
gated into the Nco1/BamH1 sites of the retrovirus vector MFG as previ-
ously described (Eming et al., 1995). The fidelity of the insert was verified
by DNA sequencing. To generate cell lines producing recombinant retro-
virus, plasmid DNAs encoding MFG-sEGF and MFG-EGF-Ct were
transfected into the 
 
C
 
-CRIP packaging cell line as described (Danos and
Mulligan, 1988). Clones of transfectants were isolated and screened for
those producing the highest viral titer.
Cells were transfected with retrovirus stock using polybrene and grown
for 2 d before plating at clonal density in medium lacking EGF. Individual
colonies were isolated using cloning rings and then screened by immuno-
fluorescence and by measuring the medium for the presence of EGF as
described below. All experiments were done with several independently
isolated colonies and all yielded the same results.
 
Organization of HMEC
 
Matrigel was brought to 4
 
8
 
C and 0.7 ml was placed in each well of a 12-
well plate on ice. The matrix was carefully overlaid with 1 ml of ice-cold
MCDB 170 to achieve a flat interface and the plates were transferred to a
37
 
8
 
C incubator for 1 h to solidify the Matrigel. The matrix was allowed to
equilibrate overnight with 2 ml of appropriate growth medium before
adding cells. The cells were removed from stock plates with trypsin,
counted, and then 200,000 cells/well were added to the equilibrated Matri-
gel. After plating, the cells were examined daily and photographed.
 
Measurement of EGF and EGFR
 
A sandwich ELISA was developed to measure EGF levels in the medium.
High binding ELISA plates (Corning
 
 
 
Glass Works, Corning, NY) were
coated with 50 
 
m
 
l of monoclonal antibody HA against EGF (5Ð10 
 
m
 
g/ml)
diluted in phosphate-buffered saline, pH 7.4, with 0.02% sodium azide
(PBSN). The plates were rinsed four times with wash buffer (0.05%
Tween-20 in PBSN) before each new addition. The plates were then
blocked using blocking buffer (10% horse sera in PBSN). Human recom-
binant EGF was diluted in blocking buffer for a standard curve ranging
from 3 to 100 pg. A rabbit polyclonal serum directed against EGF was
used as a secondary antibody diluted 1:100 in blocking buffer. Alkaline
phosphatase-conjugated goat antiÐrabbit antibody (Sigma Chemical Co.,
St. Louis, MO) was used as the tertiary antibody at a dilution of 1:6,000.
The ELISA was developed by rinsing the plates twice with 10 mM dietha-
nolamine, 0.5 mM MgCl
 
2
 
, pH 9.5, and then adding 50 
 
m
 
l of 1 mg/ml dini-
trophenol (Sigma Chemical Co.) dissolved in the same buffer. The reac-
tion was allowed to go for 4Ð10 min, and then quenched with 0.1 M
EDTA. The ELISA plates were read at 405 nm using a SpectraMax mi-
croplate reader.
A sandwich ELISA was developed to measure total EGFR levels in
cell extracts. The protocol is the same as for sEGF above, with the substi-
tution of monoclonal antibody 13A9 against the EGFR (10 
 
m
 
g/ml) and
polyclonal antiÐEGFR antiserum #448 at a 1:250. Cells were extracted
(250 
 
m
 
l per 10-cm dish) in 50 mM HEPES (pH 7.0), 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 4 mM sodium iodoacetate, 1 mM EGTA, and
10 
 
m
 
g/ml each of aprotinin, leupeptin, chymostatin, and pepstatin. Cells
were removed by scraping, transferred to 1.5-ml microfuge tubes, and in-
cubated at 0
 
8
 
C for 10 min. Cell debris was removed by centrifugation at
10,000 
 
g
 
 for 10 min. Protein concentrations were normalized between all
samples before the assay using the BCA assay (Pierce Chemical Co.).
A431 cell membranes were used as relative EGFR standards (Wiley,
1988). The addition of EGF to the A431 cell membranes confirmed that
the EGFR ELISA did not discriminate between empty and occupied re-
ceptors.
 
Growth Rates
 
To determine the relative growth rates of cells expressing the different
EGF constructs, confluent cultures were removed from their plates (6 cm)
by trypsin and resuspended in 10 ml of DFCI-1 medium lacking EGF. Al-
iquots of cells were counted and 15,000 cells were seeded into each 3.5-cm
dish. After allowing the cells to attach overnight, the medium was changed
to DFCI-1 lacking EGF or that containing either 12.5 ng/ml of EGF of 10
 
m
 
g/ml antiÐEGFR mAb 225. Every 2 d, duplicate plates from each group
were harvested and cell number was determined with a counter (Coulter
Immunology, Hialeah, FL). Culture medium was changed every 2 d.
To measure clonal growth of cells, confluent cultures of cells were re-
moved from their plates with trypsin, diluted 1:800 with DFCI-1 medium
lacking EGF, and plated in 6-cm dishes. 
 
z
 
18 h later, the medium was
changed to DFCI-1 lacking EGF or that containing either 12.5 ng/ml of
EGF of 10 
 
m
 
g/ml antiÐEGFR mAb 225. Cultures were allowed to grow for
3 wk and the media were changed every 3 d. The cells were fixed in 50%
methanol and stained with 0.4% Giemsa (Sigma Chemical Co.).
 
Shc Protein Phosphorylation
 
Cells from 100-mm plates were removed by scraping, pelleted, and ex-
tracted for 10 min on ice using 100 
 
m
 
l of 1% Triton X-100, 50 mM Tris, pH
7.2, 150 mM NaCl, 10% glycerol, 10 mM Na pyrophosphate, 1 mM
EGTA, 10 mM iodoacetic acid, 1 mM sodium orthovanadate, 10 mM NaF,
10 
 
m
 
g/ml aprotinin, chymostatin, leupeptin, and pepstatin. After centrifu-
gation to remove debris, protein concentrations of all samples were nor-
malized. AntiÐShc antibodies (Transduction Laboratories, Lexington,
KY) cross-linked to Protein A Sepharose (20Ð30 
 
m
 
l packed beads, 
 
z
 
2 
 
m
 
g
of antibody) were added to each sample, which was incubated at 4
 
8
 
C with
rocking for 1.5 h. The resulting Shc-antiÐShc bead complex was washed
twice in 1% Triton extraction buffer (see above), and then boiled in SDS-
PAGE sample buffer before electrophoresis on 5Ð15% gradient gels.
Samples were transferred to nitrocellulose and probed with RC20 an-
tiphosphotyrosine antibody coupled to horseradish peroxidase (Transduc-
tion Laboratories). The blots were then developed with Western View
ECL reagent (Transduction Laboratories).
 
Fluorescence Microscopy
 
Cells were plated on fibronectin-coated coverslips 48 h before the experi-
ment. Cells were fixed for 10 min with freshly prepared 3.6% paraformal-
dehyde and 0.024% saponin in Ca
 
2
 
1
 
, Mg
 
2
 
1
 
-free phosphate buffered sa-
line. Free aldehyde groups were quenched with 0.1% NaBH
 
4
 
 for 5 min.
Cells were incubated simultaneously with antiÐEGFR mAb 225 (10 
 
m
 
g/
ml) and antiÐEGF rabbit polyclonal Z-12 (Santa Cruz Biotechnology,
Santa Cruz, CA) in 0.012% saponin for 1 h followed by staining with
FITC-labeled goat antiÐmouse and Texas red-labeled goat antiÐrabbit
IgG antibodies (Molecular Probes, Inc., Eugene, OR) for 45 min. Alter-
nately, antiÐEGFR mAb 13A9 and antiÐEGF mAb HA were directly la- 
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beled with Alexa 488 and Alexa 594 dyes (Molecular Probes, Inc.) and
used at a concentration of 1 
 
m
 
g/ml each. Coverslips were mounted in Pro-
Long antifade medium (Molecular Probes, Inc.) and viewed with a Nikon
inverted fluorescence microscope with 60 or 100
 
3
 
 oil immersion objec-
tives. Images (12 bit, 656 
 
3 
 
517) were acquired using a Photometrics
cooled CCD camera with a Macintosh workstation running Openlab 2.0
software (Improvision, Inc., Boston, MA). For digital confocal microscopy,
image triplets were acquired 0.4-
 
m
 
m apart centered on the perinuclear en-
dosomes at 520 and 615 nm (for Alexa 488 and Alexa 594, respectively).
The image sets were deconvolved using nearest-neighbor subtraction
(Agard et al., 1989). The deconvolved images of both EGF and EGFR
distributions were then used to generate binary images using grayscale
values between 400 and 4,095. A logical ÒANDÓ between these images
was then used to determine the colocalization between the EGF and the
EGFR. The deconvolution routines were calibrated using 15-
 
m
 
m Focal-
Check beads (Molecular Probes, Inc.).
 
Results
 
Expression of Modified EGF Ligands in HMEC
 
The proteolytic processing of membrane-anchored EGFR
ligands can be complex, giving rise to multiple forms of
both soluble and membrane-anchored proteins (Derynck,
1992; Thorne and Plowman, 1994; Goishi et al., 1995). To
simplify the interpretation of our experiments, we con-
structed the two artificial EGF genes diagramed in Fig. 1
 
A
 
. Both lack the amino terminus extension that is fre-
quently proteolytically removed. A signal sequence de-
rived from the EGFR was substituted for the normal
amino terminus extension. The sEGF construct terminates
Figure 1. Expression of modified EGFR ligands in HMEC. (A) Maps of the constructs expressed in HMEC. Top map defines the do-
mains found in native EGF. The core domain binds to the EGFR and is responsible for its biological activity. (B) Size of the EGF con-
structs expressed in HMEC. Conditioned medium from cells expressing sEGF was concentrated and applied to a Sephadex G-75 col-
umn together with molecular weight markers. Samples were collected and evaluated for EGF levels by ELISA. Elution position of the
markers are indicated by arrows. (Inset) Western blot analysis of concentrated medium from cells expressing either EGF-Ct or sEGF.
The antibody used was a polyclonal against human EGF. The standard (rhEGF) was commercially purified recombinant human EGF.
(C) Rate of EGF production by either parental HMEC (WT) or several lines expressing either sEGF or EGF-Ct. Monolayers of cells
were changed to medium lacking EGF and either with (solid bars) or without (hatched bars) 10 mg/ml 225 mAb. After 24 h, the condi-
tioned medium was collected and evaluated for EGF levels by ELISA. Cell number was determined at both the initial and collection
time points and the average was used to correct for the secretion rate. (D) Downregulation of the EGFR in either parental HMEC
(WT) or cells expressing either sEGF or EGF-Ct. Cells were incubated in the presence (solid bars) or absence (hatched bars) of 33 nM
EGF for 24 h. Cells were then extracted with detergent and the total cellular EGFR content was determined by ELISA. Data was stan-
dardized to the receptor content per microgram protein in the parental cells. 
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at amino acid 1023, which corresponds to the last amino
acid in the mature EGF ligand. The EGF-Ct construct re-
tains the entire transmembrane and cytoplasmic carboxy
terminus of the EGF precursor. These artificial EGF
genes were inserted into the retrovirus vector MFG, which
was transfected into the CRIP packaging cell line (Danos
and Mulligan, 1988). The resulting recombinant retrovi-
ruses were used to transduce the immortalized 184A1
HMEC line. Clonal cell lines were then randomly selected
and screened for both EGF mRNA and protein expres-
sion.
Conditioned medium from positive cell lines was col-
lected, concentrated, and analyzed by gel filtration and
Western blot analysis. As shown in Fig. 1 
 
B
 
, EGF activity
from supernatants of cells producing sEGF ran as a single
peak, corresponding to a molecular weight of 
 
z
 
6.6 kD.
This is slightly larger than the 6.2 kD predicted from pro-
tein sequence. Western blot analysis demonstrated that
protein released from cells producing EGF-Ct ran as two
bands, with the predominant lower band corresponding to
authentic recombinant human EGF. The sEGF migrated
primarily as the higher molecular weight product. Based
on the molecular weight values obtained from gel filtra-
tion studies, the two bands likely correspond to alternate
cleavage sites in the artificial signal sequence. We found
that the biological activity of sEGF from conditioned me-
dium was the same as commercially available recombinant
EGF as determined by its ability to stimulate EGFR auto-
phosphorylation and cell proliferation (data not shown).
Shown in Fig. 1
 
 C
 
 are the rates of EGF release from sev-
eral typical cell lines expressing either sEGF or EGF-Ct.
The parental HMEC did not release any measurable
amount of EGF into the medium, but clones expressing ei-
ther sEGF or EGF-Ct released comparable amounts of
soluble EGF at rates up to 40 ng/10
 
6
 
 cells per d. Accumu-
lation of EGF in the medium could be substantially in-
creased by adding the receptor blocking antibody 225,
indicating that the cells were capable of using a large frac-
Figure 2. Distribution of EGFR
and modified ligands in HMEC.
Parental cells (WT) and cells ex-
pressing either sEGF (clone #1)
or EGF-Ct (clone #2) were
fixed, permeabilized, and simul-
taneously stained for the EGFR
(left) or EGF (right). Exposure
times for visualizing each anti-
gen were identical using the WT
cells as the standard for EGFR
and the EGF-Ct cells as the
standard for EGF. 
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tion of the released EGF. Interestingly, if cells produced
less than 
 
z
 
10 ng EGF/10
 
6
 
 cells per d, then no EGF was de-
tected in the medium unless the endogenous EGFR were
blocked (Fig. 1 
 
C
 
). This indicates either that HMEC are
able to efficiently capture low levels of autocrine ligands
or that the released ligand does not enter the bulk medium
before receptor binding.
The clonal line secreting high levels of sEGF displayed a
75% reduction in EGFR levels, which was not reduced
further by the addition of exogenous EGF (Fig. 1 
 
D
 
), indi-
cating a maximal level of receptor downregulation. The
clonal line expressing lower levels of sEGF displayed a
corresponding lower degree of receptor downregulation.
A similar situation was observed for lines expressing EGF-
Ct (data not shown). If EGF was found in the medium in
the absence of antagonistic antiÐEGFR antibodies, EGFR
downregulation was always complete (compare sEGF
clone 1 in Fig. 1, 
 
C
 
 and 
 
D
 
). This suggests that autocrine
EGF escapes into the medium only when the EGFR are
saturated and that at least some of the cell lines make
more EGF than they can consume.
The expression of sEGF and EGF-Ct in HMEC was
also evaluated by immunofluorescence. Shown in Fig. 2
are cells stained for both the EGFR and for EGF. The
EGFR in parental HMEC were predominantly at the cell
surface and EGF staining was not above background lev-
els (Fig. 2, 
 
top
 
). Cells expressing either sEGF or EGF-Ct
displayed greatly reduced levels of EGFR, which were
predominantly located in lysosomal structures (Fig. 2,
 
middle
 
 and
 
 bottom
 
), as shown by staining parallel groups
of cells with an antibody to LAMP-2 (data not shown). As
expected for a membrane-anchored protein, EGF-Ct was
predominantly located at the cell surface (Fig. 2, 
 
bottom
right
 
). Some intracellular staining was also observed that
colocalized with the EGFR.
The sEGF displayed a very weak staining pattern, con-
sistent with its lack of a membrane-anchoring domain (Fig.
2, 
 
middle right
 
). The pattern of sEGF staining, however,
appeared to be coincident with the distribution of EGFR.
To verify this colocalization, we directly labeled antiÐ
EGFR and antiÐEGF monoclonals with fluorescent dyes
to avoid any possible cross-reactivity of secondary anti-
bodies. Cells expressing sEGF were then fixed, permeabi-
lized, and stained simultaneously with the antiÐEGF and
antiÐEGFR antibodies. The distribution of sEGF and
EGFR was then determined using digital confocal micros-
copy (Agard et al., 1989). As shown in Fig. 3, both the
EGFR and the sEGF were found in small cytoplasmic ves-
icles. The distribution of sEGF (Fig. 3, 
 
red
 
) was more re-
stricted than the EGFR (
 
green
 
), most likely due to the loss
of soluble sEGF from the permeabilized cells. Virtually all
sEGF in the cell was found colocalized with the EGFR, as
shown by yellow (Fig. 3, 
 
left
 
) and by performing a logical
AND of the EGFR and EGF images (Fig. 3, 
 
right
 
). This is
in contrast to the situation with EGF-Ct, where most of
the ligand was found associated with the cell surface (Fig.
2, 
 
bottom right
 
).
 
The Transmembrane Domain of the EGF Ligand Allows 
Interruption of Autocrine Signaling
 
Some HMEC lines produce more EGF than can be con-
sumed by the endogenous EGFR and display a maximal
extent of receptor downregulation (Fig. 1, 
 
C
 
 and 
 
D
 
). Be-
cause receptor downregulation is thought to reduce the
sensitivity of cells to subsequent EGF addition (Wiley,
1985), we were interested in determining the growth rates
of these chronically stimulated cells. The parental 184A1
cells grew in the absence of exogenous EGF, but grew to a
higher density when EGF was added (Fig. 4 
 
A
 
). Blocking
their EGFR with antagonistic mAb 225 strongly inhibited
cell growth, as previously reported (Stampfer et al., 1993).
Although the addition of EGF to cells producing sEGF
had no effect on their growth rate, these cells grew at the
same rate as parental cells treated with high concentra-
tions of exogenous EGF (Fig. 4 
 
A
 
,
 
 middle
 
). This indicates
that downregulation of EGFR does not affect the steady
state response of the cells. Surprisingly, addition of high
concentrations of antagonistic 225 mAb had no effect on
the growth rate of these cells either, indicating that the
sEGF-EGFR autocrine loop could not be interrupted. In
the case of cells expressing EGF-Ct, growth rates were
again similar to those observed for parental cells treated
with high concentrations of EGF and addition of exoge-
nous EGF again had little effect (Fig. 4 
 
A
 
,
 
 right
 
). In con-
trast to the situation with sEGF, however, the addition of
225 mAb effectively inhibited their growth. Thus, inter-
ruption of autocrine signaling in HMEC by antagonistic
EGFR antibodies appeared to require the membrane an-
choring domain of the ligand.
Because cells expressing EGF-Ct produce at least as
much ligand as those expressing sEGF (see Fig. 1 
 
C
 
), their
relative sensitivity to 225 treatment could not be explained
simply as an effect of mass action. An alternate explana-
tion could be a clonal variation between cells with respect
to their dependence on EGFR activation. We repeated
our analysis on several independently isolated clones and
Figure 3. Colocalization of sEGF and EGFR in HMEC. Cells ex-
pressing sEGF (clone #1) were fixed, permeabilized with saponin,
and incubated with directly labeled antiÐEGFR antibody 13A9
(green) or antiÐEGF antibody HA (red). Image triplets were ac-
quired with a 1003 objective and deconvolved using a nearest-
neighbor routine (left). The red image was converted to a binary
image (middle), and logically ANDÕed with a binary image of the
green image to determine colocalization (right). The small panels
beneath the main images are enlarged sections of the image. Bar,
5 mm.Wiley et al. Autocrine Regulation of Mammary Epithelial Cells 1323
observed the same effect; all clonal lines expressing sEGF
were resistant to the effect of 225 mAb. To verify that
EGFR activation itself was resistant to the effect of 225
mAb in cells expressing sEGF, we examined the phosphor-
ylation of the EGFR substrate Shc in the different cell
lines (Ruff-Jamison et al., 1993). As shown in Fig. 4 B, ad-
dition of EGF to the parental HMEC line resulted in high
levels of Shc tyrosine phosphorylation, but little Shc phos-
phorylation was observed in either the absence of EGF or
in the presence of 225 mAb. In the case of cells expressing
either sEGF or EGF-Ct, Shc phosphorylation was signifi-
cant in the absence or presence of exogenous EGF. Sig-
nificantly, the addition of 225 mAb had little effect on
Shc phosphorylation in cells expressing sEGF, but was
strongly inhibitory in cells expressing EGF-Ct. These data
demonstrate that sEGF can activate the EGFR even in the
presence of antagonistic antibodies. The simplest explana-
tion for this observation is that removal of the membrane-
anchoring domain allows EGF to bind to its receptor be-
fore arrival at the cell surface and thus to operate in an
ÒintracrineÓ fashion.
In the experiments shown in Fig. 4, A and B, cells were
grown at a relatively high density (between 0.03 and 1 3
105/cm2). As an alternate to the intracrine hypothesis,
sEGF could be trapped between cells and thus could bind
to EGFR before the antagonistic antibody could diffuse to
the cell surface. The more slowly released EGF-Ct would
potentially not have such a kinetic advantage. If sEGF was
operating in an intracrine manner, then growth of cells
producing sEGF should be independent of cell density. If
sEGF was simply being trapped between cells, then lower-
ing the cell density should allow the 225 mAb to block re-
ceptor activation. To test this idea, cells were plated at
clonal densities (,100 per cm2) and grown for several
weeks in the presence or absence of antiÐEGFR antibod-
ies. As shown in Fig. 5, 225 mAb was unable to block the
growth of cells producing sEGF, but were completely ef-
fective in preventing growth of either the parental cell line
or cells producing EGF-Ct. These data demonstrate that
even at the single cell level, autocrine signaling mediated
by sEGF cannot be interrupted.
Spatial Organization of HMEC Is Disrupted by
Secreted EGF
It has been shown previously that activation of the EGFR
is important in proliferation and motility of HMEC (Mat-
thay et al., 1993; Stampfer et al., 1993). We have found
that EGFR signaling is also required for these cells to
form three-dimensional structures on a reconstituted base-
ment membrane. As shown in Fig. 6, when cells from the
184 line were plated on extracellular matrix (Matri-
gel) derived from Englebreth-Holme-Swarm fibrosar-
coma (Schuetz et al., 1988), they rapidly assemble into
epithelial cords and form complex three-dimensional
structures. Colonies mature over 4 to 10 d to form a com-
Figure 4. Autocrine signaling by
sEGF cannot be interrupted. (A)
Proliferation of HMEC. Equal
numbers of each cell type were
plated into dishes without EGF
(s) or either with 20 nM EGF
(d) or 10 mg/ml of 225 mAb (h).
Cell number was determined in
duplicate at the indicated times.
The medium was changed every
other day. (B) Phosphorylation
of the EGFR substrate Shc. Cells
treated either with 20 nM EGF
for 5 min or 10 mg/ml of 225
mAb for 18 h were extracted and
total cellular Shc was immuno-
precipitated. After electrophore-
sis and transfer to nitrocellulose,
the blots were probed with
antiphosphotyrosine antibodies.
Arrows indicate the 66-kD Shc-
related protein and the 53 and 46
kD forms of Shc.The Journal of Cell Biology, Volume 143, 1998 1324
plex branched network with multiple endbuds that super-
ficially resemble alveolar complexes in vivo. Occupancy
of the EGFR was essential for HMEC organization on
Matrigel because antagonistic antiÐEGFR mAb 225 effi-
ciently inhibited formation of complex structures (Fig. 6).
Blocking EGFR occupancy after formation of initial ag-
gregates also prevented the appearance of mature struc-
tures (data not shown).
The effect of mAb 225 on cell organization was not due
to cell toxicity. Previously, it has been shown that mAb
225 causes a reversible entry into G0 of the cell cycle
(Stampfer et al., 1993). We have found that high concen-
trations of EGF will readily reverse the effects of 225
mAb. In addition, no apoptosis was observed in 225-
treated cells (data not shown).
Organization of 184A1 HMEC was dependent on both
time and cell density. Increasing numbers of 184A1 cells
were plated on Matrigel in either the presence or absence
of exogenous EGF. As shown in Fig. 7, within 24 h the
cells were able to form simple branching structures. Be-
cause the doubling time of these cells is 18Ð24 h (Stampfer
and Yaswen, 1994), cell proliferation is unlikely to play a
major role in formation of the initial structures. In the
absence of exogenous EGF, a cell density of at least 105
cells/cm2 was required for organization. In the presence of
EGF, a density of only 2 3 104 cells/cm2 was necessary. In
the absence of exogenous EGF, the cells primarily formed
branching structures that were stable over time (Fig. 7,
left). The addition of exogenous EGF stimulated forma-
tion of endbud-like structures (Fig. 7, right), most likely by
stimulating cell proliferation. The addition of antiÐEGFR
mAb 225 completely blocked organization of the cells at
all time points (data not shown; also see below).
There was also a time window of z12Ð24 h during which
exogenous EGF facilitated organization of 184A1 cells.
Visual observations suggested that this was related to in-
vasion of the Matrigel by the cells. Thus, if EGF was pro-
vided to cells while they were still on the surface of the ex-
tracellular matrix, the cells could organize, but EGF had
Figure 5. Expression of sEGF allows clonal growth of HMEC in
the presence of antiÐEGFR antibodies. Parental cells (WT) and
cells expressing either sEGF (clone #1) or EGF-Ct (clone #2)
were seeded at a density of ,100 per cm2 into 60-mm dishes and
cultured for 3 wk in the presence of control medium lacking ex-
ogenous EGF, or with either 2 nM EGF or 10 mg/ml 225 mAb.
The cells were then stained with crystal violet.
Figure 6. Organization of HMEC on Matrigel requires activation
of EGFR. Cells (line 184) were plated on thick layers of Matrigel
at a cell density of 2.5 3 104 cells/cm2 in the presence of 2 nM
EGF for the indicated lengths of time. Cells incubated in 225
mAb (bottom right) were cultured for 2 d in the presence of 10
mg/ml of the antibody and in the absence of exogenous EGF.
Photos were taken using phase optics. Bars, z200 mm.
Figure 7. Organization of HMEC in the absence of exogenous
EGF is dependent on cell density. The indicated number of cells
(5 3 104, 105, and 2 3 105) were plated on thick layers of Matrigel
cast in six well culture dishes either in the presence or absence of
2 nM EGF. Photographs were taken of the center of the wells
(43 phase objectives) after either 24 (left) or 72 (right) h. Arrows
indicate individual cells isolated from the main organizing struc-
tures.Wiley et al. Autocrine Regulation of Mammary Epithelial Cells 1325
little effect once the cells entered the matrix. As indicated
in Fig. 7 by the arrows, cells not included in a structure by
24 h remained as isolated colonies. The addition of EGF
greatly increased the fraction of cells that joined organized
structures, suggesting that cell migration and cellÐcell con-
tact were important aspects of EGF-stimulated organiza-
tion.
We examined the effect of noninterruptible autocrine/
intracrine signaling on cell organization by observing the
ability of HMEC expressing either sEGF or EGF-Ct to
form complex structures. Cells were plated on Matrigel at
a relatively low density (1.3 3 104/cm2) so that the effects
of different EGF levels could be observed (see Fig. 7). Af-
ter 6 d, their state of organization was evaluated. As
shown in Fig. 8, parental cells formed small aggregates in
the absence on exogenous EGF. As expected, the addition
of EGF resulted in the formation of well defined complex
structures. Again, addition of antiÐEGFR antibody 225
blocked cell organization in the parental HMEC cells.
Cells expressing sEGF formed large aggregates that in-
creased in size over time, but did not make organized
structures (Fig. 8). In particular, the ability of these cells to
form tubular or ductlike structures was severely affected.
The addition of exogenous EGF or antagonistic 225 mAb
had no effect on growth or organization of cells expressing
sEGF.
In contrast to the effect of sEGF production, expression
of EGF-Ct facilitated the formation of structures with
clear lobular and ductal aspects (Fig. 8). The addition of
exogenous EGF partially inhibited the formation of struc-
tures, whereas the addition of antagonistic 225 mAb com-
pletely blocked the process. If the cells were cultured for
an additional 14 d, the structures formed by the parental
HMEC were stable, but those formed by cells expressing
EGF-Ct became less defined (data not shown). These ob-
servations indicate that both the concentration of EGF
and its spatial presentation to receptors is important in its
ability to facilitate the organization of HMEC in culture.
Discussion
The data presented here demonstrate that the membrane-
anchoring domain of EGFR ligands may play an impor-
tant role in regulating the cellular location of EGFR acti-
vation. Most studies on EGFR regulation have been
focused at the receptor level, but ligand availability is gen-
erally rate-limiting in the overall activity of the EGFR
pathway, as demonstrated by increased growth rate and
density of autocrine cells after adding exogenous ligand
(Atlas et al., 1992; Hashimoto et al., 1994). Release of
EGFR ligands is itself a regulated process and appears to
depend on the structure of the membrane-anchoring do-
main (Pandiella et al., 1992; Bosenberg et al., 1993; Mas-
sagu and Pandiella, 1993; Goishi et al., 1995; Baselga et al.,
1996). Our investigation indicates that the membrane an-
choring domain of the ligand also serves to restrict the site
of ligand release. This spatial restriction appears to be im-
portant in normal cell function.
There is abundant evidence to show that EGFR func-
tion is critically important in both the formation and dif-
ferentiated function of mammary glands (Snedeker et al.,
1991; Fowler et al., 1995; Xie et al., 1997). Our HMEC ex-
perimental system appears to recapitulate some of the
EGFR-dependent organization processes observed in
vivo, although we did not observe differentiation of the
cells into glandular epithelium (data not shown). Recent
work suggests that differentiation requires the presence of
multiple cell types (Gomm et al., 1997).
HMEC make a variety of different EGFR ligands, with
TGFa and amphiregulin appearing the most important (Li
et al., 1992). The simultaneous expression of a number of
different EGFR ligands in a homogeneous cell population
may indicate that different ligands have distinct functions.
As a first step towards understanding structureÐfunction
relationships in EGFR ligands, we expressed EGF either
with or without a membrane-anchoring domain. Removal
of the membrane-anchoring domain of amphiregulin has
been shown to alter the proteolytic processing of its
amino-terminal extension, presumably by altering access
to the processing enzymes (Thorne and Plowman, 1994).
To simplify the analysis of our experiments, our EGF con-
structs lacked any amino-terminus extension.
We found that the most striking effect of removing the
membrane anchoring domain of EGF was the loss of our
ability to block EGFR signaling with antagonistic antire-
ceptor antibodies. This was observed at all cell densities.
Immunofluorescent imaging of cells expressing both sEGF
and EGFR showed extensive colocalization in intracellu-
lar vesicles, indicating intracrine signaling. Because the
ligand and antibody binding sites on the EGFR are over-
lapping and mutually exclusive (Gill et al., 1984), pre-
formed EGF-receptor complexes arriving at the cell sur-
face would not be affected by antagonistic antibodies. In
Figure 8. Expression of sEGF prevents HMEC from organizing
into organotypic structures on Matrigel. Parental cells (WT) and
cells expressing either sEGF (clone #1) or EGF-Ct (clone #2)
were seeded at a density of 1.3 3 104/cm2 in the absence of EGF
(Control), in the presence of 2 nM EGF (1EGF) or 10 mg/ml 225
antiÐEGFR antibodies (1225). After 6 d, photographs were
made using 43 phase objectives.The Journal of Cell Biology, Volume 143, 1998 1326
contrast, we found that cells expressing membrane-
anchored EGF-Ct were readily inhibited by antibodies.
This indicates that membrane-anchored EGF and the
EGFR are separate upon delivery to the cell surface.
Thus, the formation of complexes between EGF-Ct and
the EGFR either requires proteolytic release of EGF from
the cell surface or any juxtacrine signaling must be re-
stricted to the cell surface.
Juxtacrine activity has been described for membrane-
anchored EGF and TGFa, as well as for HB-EGF (Brach-
mann et al., 1989; Mroczkowski et al., 1989; Wong et al.,
1989; Higashiyama et al., 1995; Baselga et al., 1996). The
relative contribution of membrane-anchored and soluble
ligand forms to total ligand activity in vivo is unclear. If the
membrane-anchored forms of the ligands do play a signifi-
cant biological role, however, there must be specialized
mechanisms to restrict receptor activation to the cell sur-
face. CD9/DRAP 27 has been identified as an auxiliary
molecule that facilitates juxtacrine signaling in the case of
HB-EGF (Higashiyama et al., 1995). One of its roles could
be to restrict juxtacrine signaling to the cell surface.
Restriction of EGFR signaling to the cell surface ap-
pears to be necessary for organization of HMEC on Matri-
gel. Cells incubated with exogenous EGF, or expressing
membrane-anchored EGF, formed complex structures
that superficially resembled ducts and endbuds. Expres-
sion of sEGF resulted in the disruption of the structures.
This dominant, disorganizing effect of sEGF could indi-
cate that intracrine signaling results in the phosphoryla-
tion of inappropriate intracellular substrates. However, we
have not observed any significant differences between ty-
rosine-phosphorylated substrates in cells expressing sEGF
versus EGF-Ct (data not shown). Alternately, the pattern
of receptor occupancy at the cell surface could provide
clues regarding the extracellular environment that could
be important in cell organization. The uniform occupancy
by sEGF of all EGFR before arrival at the cell surface
would destroy any pattern of signaling imposed by the ex-
tracellular environment. The addition of exogenous EGF
would not mimic the action of sEGF because its access to
the cell surface is also spatially restricted by cellÐcell and
cellÐmatrix contacts. In either case, our results do show
that the cellular location of EGFR signaling can have a
significant effect on cell behavior.
All of the currently identified EGFR ligands, such as
EGF, TGFa, amphiregulin, HB-EGF, and betacellulin,
are made as membrane-associated precursors (Massagu
and Pandiella, 1993). It is interesting to note that a number
of virally encoded EGFR ligands have been identified,
such as myxoma growth factor (Upton et al., 1987) and
Shope fibroma growth factor (Chang et al., 1987). Unlike
the normal EGFR ligands, these viral ligands lack a mem-
brane anchoring domain. This may promote proliferation
of infected cells by circumventing the normal mechanisms
that regulate or interrupt autocrine signaling. Consistent
with this hypothesis is the observation that Shope fibroma
growth factor is a major virulence factor in malignant
rabbit fibroma virus pathogenicity and is involved in pro-
moting epithelial hyperplasia and squamous metaplasia
(Opgenorth et al., 1992). Another pathological auto-
crine  system is the v-sis/PDGF receptor system. Although
PDGF is normally a paracrine growth factor (Battegay et al.,
1994), inappropriate simultaneous expression of the ligand
with the receptor results in uncontrolled cell proliferation
(Chiu et al., 1984). An intracrine mechanism for v-sis sig-
naling has been proposed as well (Bejcek et al., 1989), al-
though the requirement of the ligand-receptor complex to
reach the surface is controversial (Lee and Donoghue,
1992).
We found that unless cells made a greater amount of
EGF than they could consume, little ligand was found in
the extracellular medium unless the EGFR were blocked.
A similar observation has been made in the case of
MDCK cells expressing TGFa (Dempsey and Coffey,
1994). This suggests that either released ligand does not
enter the bulk medium before binding to the EGFR, or
that the cells are extremely efficient in binding low con-
centrations of ligands. It does show, however, that the lack
of ligand in the extracellular medium does not indicate the
absence of autocrine signaling.
A major theme emerging in the field of signal transduc-
tion is that alterations in the spatial distribution of signal-
ing molecules is important for their activation (Carraway
and Carraway, 1995; Leevers et al., 1994). This spatial
distribution could drive morphogenic processes. It has
already been shown that in Caenorhabditis elegans, the
pattern of LET-23 receptor localization is important for
lin-3Ðmediated vulval development (Simske et al., 1996).
Because the LET-23/lin-3 pair is homologous to the mam-
malian EGFR system (Aroian et al., 1994), perhaps it is
not surprising that disruption of autocrine ligand distribu-
tion should have a pronounced effect on cell organization.
Because autocrine signaling is important in dictating tissue
organization, it may play a more important role in devel-
opment than previously suspected.
We thank Martha Stampfer for the 184 and 184A1 cells. 
This work was supported by grant DAMD17-94-J-444 from the United
States Army Breast Cancer Research Program (USABCRP). The authors
also gratefully acknowledge financial support from a grant from the Na-
tional Science Foundation Biotechnology Program, Division of Bioengi-
neering and Environmental Systems. This work used the Flow Cytometry,
Cell Imaging, and Oligonucleotide Synthesis core facilities of the Hunts-
man Cancer Institute, supported by National Cancer Institute Cancer
Center Support Grant grant 5P30 CA 42014. P.M. Burke is a recipient of a
predoctoral fellowship from the USABCRP.
Received for publication 22 April 1998 and in revised form 11 September
1998.
References
Agard, D.A., Y. Hiraoka, P. Shaw, and J.W. Sedat. 1989. Fluorescence micros-
copy in three dimensions. In Fluorescence Microscopy of Living Cells in
Culture. Vol. 30. D.L. Taylor and Y.L. Wang, editors. Academic Press, San
Diego, CA. 353Ð377.
Alroy, I., and Y. Yarden. 1997. The ErbB signaling network in embryogenesis
and oncogenesis: signal diversification through combinatorial ligandÐrecep-
tor interactions. FEBS Lett. 410:83Ð86.
Anklesaria, P., J. Teixido, M. Laiho, J.H. Pierce, J.S. Greenberger, and J. Mas-
sagu. 1990. CellÐcell adhesion mediated by binding of membrane-anchored
transforming growth factor alpha to epidermal growth factor receptors pro-
motes cell proliferation. Proc. Natl. Acad. Sci. USA. 87:3289Ð3293.
Aroian, R.V., G.M. Lesa, and P.W. Sternberg. 1994. Mutations in the Cae-
norhabditis elegans let-23 EGFR-like gene define elements important for
cell-type specificity and function. EMBO (Eur. Mol. Biol. Organ.) J. 13:360Ð366.
Atlas, I., J. Mendelsohn, J. Baselga, W.R. Fair, H. Masui, and R. Kumar. 1992.
Growth regulation of human renal carcinoma cells: role of transforming
growth factor alpha. Cancer Res. 52:3335Ð3339.
Band, V., and R. Sager. 1989. Distinctive traits of normal and tumor-derived
human mammary epithelial cells expressed in a medium that supports long-
term growth of both cell types. Proc. Natl. Acad. Sci. USA. 86:1249Ð1253.Wiley et al. Autocrine Regulation of Mammary Epithelial Cells 1327
Barnard, J.A., R. Graves-Deal, M.R. Pittelkow, R. DuBois, P. Cook, G.W.
Ramsey, P.R. Bishop, L. Damstrup, and R.J. Coffey. 1994. Auto- and cross-
induction within the mammalian epidermal growth factor-related peptide
family. J. Biol. Chem. 269:22817Ð22822.
Barrandon, Y., and H. Green. 1987. Cell migration is essential for sustained
growth of keratinocyte colonies: the roles of transforming growth factor-
alpha and epidermal growth factor. Cell. 50:1131Ð1137.
Baselga, J., J. Mendelsohn, Y.M. Kim, and A. Pandiella. 1996. Autocrine regu-
lation of membrane transforming growth factorÐalpha cleavage. J. Biol.
Chem. 271:3279Ð3284.
Battegay, E.J., J. Rupp, L. Iruela-Arispe, E.H. Sage, and M. Pech. 1994. PDGF-
BB modulates endothelial proliferation and angiogenesis in vitro via PDGF
beta-receptors. J. Cell Biol. 125:917Ð928.
Beerli, R.R., and N.E. Hynes. 1996. Epidermal growth factorÐrelated peptides
activate distinct subsets of ErbB receptors and differ in their biological activ-
ities. J. Biol. Chem. 271:6071Ð6076.
Bejcek, B.E., D.Y. Li, and T.F. Deuel. 1989. Transformation by v-sis occurs by
an internal autoactivation mechanism. Science. 245:1496Ð1499.
Besner, G.E., D. Whelton, M.A. Crissman-Combs, C.L. Steffen, G.Y. Kim, and
D.R. Brigstock. 1992. Interaction of heparin-binding EGF-like growth factor
(HB-EGF) with the epidermal growth factor receptor: modulation by hep-
arin, heparinase, or synthetic heparin-binding HB-EGF fragments. Growth
Factors. 7:289Ð296.
Bosenberg, M.W., A. Pandiella, and J. Massagu. 1993. Activated release of
membrane-anchored TGF-alpha in the absence of cytosol. J. Cell Biol. 122:
95Ð101.
Brachmann, R., P.B. Lindquist, M. Nagashima, W. Kohr, T. Lipari, M. Napier,
and R. Derynck. 1989. Transmembrane TGF-alpha precursors activate
EGF/TGF-alpha receptors. Cell. 56:691Ð700.
Carpenter, G., and S. Cohen. 1990. Epidermal growth factor. J. Biol. Chem.
265:7709Ð7712.
Carraway, K.L., and C.A. Carraway. 1995. Signaling, mitogenesis and the cy-
toskeleton: where the action is. Bioessays. 17:171Ð175.
Chang, W., C. Upton, S.L. Hu, A.F. Purchio, and G. McFadden. 1987. The ge-
nome of Shope fibroma virus, a tumorigenic poxvirus, contains a growth fac-
tor gene with sequence similarity to those encoding epidermal growth factor
and transforming growth factor alpha. Mol. Cell. Biol. 7:535Ð540.
Chiu, I.M., E.P. Reddy, D. Givol, K.C. Robbins, S.R. Tronick, and S.A. Aaron-
son. 1984. Nucleotide sequence analysis identifies the human c-sis proto-onco-
gene as a structural gene for platelet-derived growth factor. Cell. 37:123Ð129.
Cook, P.W., N.M. Ashton, C.E. Karkaria, D.C. Siess, and G.D. Shipley. 1995.
Differential effects of a heparin antagonist (hexadimethrine) or chlorate on
amphiregulin, basic fibroblast growth factor, and heparin-binding EGF-like
growth factor activity. J. Cell Physiol. 163:418Ð429.
Danos, O., and R.C. Mulligan. 1988. Safe and efficient generation of recombi-
nant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl.
Acad. Sci. USA. 85:6460Ð6464.
Dempsey, P.J., and R.J. Coffey. 1994. Basolateral targeting and efficient con-
sumption of transforming growth factor-alpha when expressed in Madin-
Darby canine kidney cells. J. Biol. Chem. 269:16878Ð16889.
Dempsey, P.J., K.S. Meise, Y. Yoshitake, K. Nishikawa, and R.J. Coffey. 1997.
Apical enrichment of human EGF precursor in Madin-Darby canine kidney
cells involves preferential basolateral ectodomain cleavage sensitive to a
metalloprotease inhibitor. J. Cell Biol. 138:747Ð758.
Derynck, R. 1992. The physiology of transforming growth factor-alpha. Adv.
Cancer Res. 58:27Ð52.
Downing, M.T., D.R. Brigstock, M.H. Luquette, M. Crissman-Combs, and G.E.
Besner. 1997. Immunohistochemical localization of heparin-binding epider-
mal growth factor-like growth factor in normal skin and skin cancers. His-
tochem. J. 29:735Ð744.
Earp, H.S., T.L. Dawson, X. Li, and H. Yu. 1995. Heterodimerization and func-
tional interaction between EGF receptor family members: a new signaling
paradigm with implications for breast cancer research. Breast Cancer Res.
Treat. 35:115Ð132.
Ebner, R., and R. Derynck. 1991. Epidermal growth factor and transforming
growth factor-alpha: differential intracellular routing and processing of
ligand-receptor complexes. Cell Regul. 2:599Ð612.
Eming, S.A., J. Lee, R.G. Snow, R.G. Tompkins, M.L. Yarmush, and J.R. Mor-
gan. 1995. Genetically modified human epidermis overexpressing PDGF-A
directs the development of a cellular and vascular connective tissue stroma
when transplanted to athymic miceÑimplications for the use of genetically
modified keratinocytes to modulate dermal regeneration. J. Invest. Derma-
tol. 105:756Ð763.
Engler, D.A., R.K. Matsunami, S.R. Campion, C.D. Stringer, A. Stevens, and
S.K. Niyogi. 1988. Cloning of authentic human epidermal growth factor as a
bacterial secretory protein and its initial structure-function analysis by site-
directed mutagenesis. J. Biol. Chem. 263:12384Ð12390.
Fisher, D.A., E.C. Salido, and L. Barajas. 1989. Epidermal growth factor and
the kidney. Annu. Rev. Physiol. 51:67Ð80.
Fowler, K.J., F. Walker, W. Alexander, M.L. Hibbs, E.C. Nice, R.M. Bohmer,
G.B. Mann, C. Thumwood, R. Maglitto, J.A. Danks, et al. 1995. A mutation
in the epidermal growth factor receptor in waved-2 mice has a profound ef-
fect on receptor biochemistry that results in impaired lactation. Proc. Natl.
Acad. Sci. USA. 92:1465Ð1469.
French, A.R., D.K. Tadaki, S.K. Niyogi, and D.A. Lauffenburger. 1995. Intra-
cellular trafficking of epidermal growth factor family ligands is directly influ-
enced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem.
270:4334Ð4340.
Gill, G.N., T. Kawamoto, C. Cochet, A. Le, J.D. Sato, H. Masui, C. McLeod,
and J. Mendelsohn. 1984. Monoclonal anti-epidermal growth factor receptor
antibodies which are inhibitors of epidermal growth factor binding and an-
tagonists of epidermal growth factor-stimulated tyrosine protein kinase ac-
tivity. J. Biol. Chem. 259:7755Ð7760.
Gill, G.N., and W. Weber. 1987. Purification of functionally active epidermal
growth factor receptor protein using a competitive antagonistic monoclonal
antibody and a competitive elution with epidermal growth factor. Methods
Enzymol. 146:82Ð88.
Goishi, K., S. Higashiyama, M. Klagsbrun, N. Nakano, T. Umata, M. Ishikawa,
E. Mekada, and N. Taniguchi. 1995. Phorbol ester induces the rapid process-
ing of cell surface heparin-binding EGF-like growth factor: conversion from
juxtacrine to paracrine growth factor activity. Mol. Biol. Cell. 6:967Ð980.
Gomm, J.J., R.C. Coope, P.J. Browne, and R.C. Coombes. 1997. Separated hu-
man breast epithelial and myoepithelial cells have different growth factor re-
quirements in vitro but can reconstitute normal breast lobuloalveolar struc-
ture. J. Cell. Physiol. 171:11Ð19.
Hammond, S.L., R.G. Ham, and M.R. Stampfer. 1984. Serum-free growth of
human mammary epithelial cells: rapid clonal growth in defined medium
and extended serial passage with pituitary extract. Proc. Natl. Acad. Sci.
USA. 81:5435Ð5439.
Hashimoto, K., S. Higashiyama, H. Asada, E. Hashimura, T. Kobayashi, K.
Sudo, T. Nakagawa, D. Damm, K. Yoshikawa, and N. Taniguchi. 1994. Hep-
arin-binding epidermal growth factor-like growth factor is an autocrine
growth factor for human keratinocytes. J. Biol. Chem. 269:20060Ð20066.
Higashiyama, S., J.A. Abraham, J. Miller, J.C. Fiddes, and M. Klagsbrun. 1991.
A heparin-binding growth factor secreted by macrophage-like cells that is
related to EGF. Science. 251:936Ð939.
Higashiyama, S., R. Iwamoto, K. Goishi, G. Raab, N. Taniguchi, M. Klagsbrun,
and E. Mekada. 1995. The membrane protein CD9/DRAP 27 potentiates
the juxtacrine growth factor activity of the membrane-anchored heparin-
binding EGF-like growth factor. J. Cell Biol. 128:929Ð938.
Lee, B.A., and D.J. Donoghue. 1992. Intracellular retention of membrane-
anchored v-sis protein abrogates autocrine signal transduction. J. Cell Biol.
118:1057Ð1070.
Leevers, S.J., H.F. Paterson, and C.J. Marshall. 1994. Requirement for Ras in
Raf activation is overcome by targeting Raf to the plasma membrane. Na-
ture. 369:411Ð414.
Li, S., G.D. Plowman, S.D. Buckley, and G.D. Shipley. 1992. Heparin inhibition
of autonomous growth implicates amphiregulin as an autocrine growth fac-
tor for normal human mammary epithelial cells. J. Cell. Physiol. 153:103Ð111.
Luetteke, N.C., T.H. Qiu, R.L. Peiffer, P. Oliver, O. Smithies, and D.C. Lee.
1993. TGF alpha deficiency results in hair follicle and eye abnormalities in
targeted and waved-1 mice. Cell. 73:263Ð278.
Lupu, R., M. Cardillo, L. Harris, M. Hijazi, and K. Rosenberg. 1995. Interaction
between erbB-receptors and heregulin in breast cancer tumor progression
and drug resistance. Semin. Cancer Biol. 6:135Ð145.
Mann, G.B., K.J. Fowler, A. Gabriel, E.C. Nice, R.L. Williams, and A.R. Dunn.
1993. Mice with a null mutation of the TGF alpha gene have abnormal skin
architecture, wavy hair, and curly whiskers and often develop corneal in-
flammation. Cell. 73:249Ð261.
Massagu, J., and A. Pandiella. 1993. Membrane-anchored growth factors.
Annu. Rev. Biochem. 62:515Ð541.
Matthay, M.A., J.P. Thiery, F. Lafont, F. Stampfer, and B. Boyer. 1993. Tran-
sient effect of epidermal growth factor on the motility of an immortalized
mammary epithelial cell line. J. Cell Sci. 106:869Ð878.
Miettinen, P.J., J.E. Berger, J. Meneses, Y. Phung, R.A. Pedersen, Z. Werb,
and R. Derynck. 1995. Epithelial immaturity and multiorgan failure in mice
lacking epidermal growth factor receptor. Nature. 376:337Ð341.
Mroczkowski, B., M. Reich, K. Chen, G.I. Bell, and S. Cohen. 1989. Recombi-
nant human epidermal growth factor precursor is a glycosylated membrane
protein with biological activity. Mol. Cell. Biol. 9:2771Ð2778.
Opgenorth, A., D. Strayer, C. Upton, and G. McFadden. 1992. Deletion of the
growth factor gene related to EGF and TGF alpha reduces virulence of ma-
lignant rabbit fibroma virus. Virology. 186:175Ð191.
Opresko, L.K., and H.S. Wiley. 1990. Functional reconstitutional of the human
epidermal growth factor receptor system in Xenopus oocytes. J. Cell Biol.
111:1661Ð1671.
Pandiella, A., M.W. Bosenberg, E.J. Huang, P. Besmer, and J. Massagu. 1992.
Cleavage of membrane-anchored growth factors involves distinct protease
activities regulated through common mechanisms. J. Biol. Chem. 267:24028Ð
24033.
Riese, D.J., E.D. Kim, K. Elenius, S. Buckley, M. Klagsbrun, G.D. Plowman,
and D.F. Stern. 1996. The epidermal growth factor receptor couples trans-
forming growth factor-alpha, heparin-binding epidermal growth factor-like
factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem. 271:
20047Ð20052.
Ruff-Jamison, S., J. McGlade, T. Pawson, K. Chen, and S. Cohen. 1993. Epider-
mal growth factor stimulates the tyrosine phosphorylation of SHC in the
mouse. J. Biol. Chem. 268:7610Ð7612.
Saeki, T., K. Stromberg, C.F. Qi, W.J. Gullick, E. Tahara, N. Normanno, F. Ciar-
diello, N. Kenney, G.R. Johnson, and D.S. Salomon. 1992. Differential im-The Journal of Cell Biology, Volume 143, 1998 1328
munohistochemical detection of amphiregulin and cripto in human normal
colon and colorectal tumors. Cancer Res. 52:3467Ð3473.
Sakurai, H., T. Tsukamoto, C.A. Kjelsberg, L.G. Cantley, and S.K. Nigam.
1997. EGF receptor ligands are a large fraction of in vitro branching mor-
phogens secreted by embryonic kidney. Am. J. Physiol. 273:F463ÐF472.
Schneider, C., R.A. Newman, D.R. Sutherland, U. Asser, and M.F. Greaves.
1982. A one-step purification of membrane proteins using a high efficiency
immunomatrix. J. Biol. Chem. 257:10766Ð10769.
Schreiber, A.B., M.E. Winkler, and R. Derynck. 1986. Transforming growth
factor-alpha: a more potent angiogenic mediator than epidermal growth fac-
tor. Science. 232:1250Ð1253.
Schuetz, E.G., D. Li, C.J. Omiecinski, U. Muller-Eberhard, H.K. Kleinman, B.
Elswick, and P.S. Guzelian. 1988. Regulation of gene expression in adult rat
hepatocytes cultured on a basement membrane matrix. J. Cell. Physiol. 134:
309Ð323.
Shing, Y., G. Christofori, D. Hanahan, Y. Ono, R. Sasada, K. Igarashi, and J.
Folkman. 1993. Betacellulin: a mitogen from pancreatic beta cell tumors.
Science. 259:1604Ð1607.
Shoyab, M., G.D. Plowman, V.L. McDonald, J.G. Bradley, and G.J. Todaro.
1989. Structure and function of human amphiregulin: a member of the epi-
dermal growth factor family. Science. 243:1074Ð1076.
Sibilia, M., and E.F. Wagner. 1995. Strain-dependent epithelial defects in mice
lacking the EGF receptor. Science. 269:234Ð238.
Simske, J.S., S.M. Kaech, S.A. Harp, and S.K. Kim. 1996. LET-23 receptor lo-
calization by the cell junction protein LIN-7 during C. elegans vulval induc-
tion. Cell. 85:195Ð204.
Snedeker, S.M., C.F. Brown, and R.P. DiAugustine. 1991. Expression and func-
tional properties of transforming growth factor alpha and epidermal growth
factor during mouse mammary gland ductal morphogenesis. Proc. Natl.
Acad. Sci. USA. 88:276Ð280.
Stampfer, M.R., A. Bodnar, J. Garbe, M. Wong, A. Pan, B. Villeponteau, and
P. Yaswen. 1997. Gradual phenotypic conversion associated with immortal-
ization of cultured human mammary epithelial cells. Mol. Biol. Cell. 8:2391Ð
2405.
Stampfer, M.R., C.H. Pan, J. Hosoda, J. Bartholomew, J. Mendelsohn, and P.
Yaswen. 1993. Blockage of EGF receptor signal transduction causes revers-
ible arrest of normal and immortal human mammary epithelial cells with
synchronous reentry into the cell cycle. Exp. Cell Res. 208:175Ð188.
Stampfer, M.R., and P. Yaswen. 1994. Growth, differentiation, and transforma-
tion of human mammary epithelial cells in culture. Cancer Treat. Res. 71:29Ð48.
Thompson, S.A., S. Higashiyama, K. Wood, N.S. Pollitt, D. Damm, G. McEn-
roe, B. Garrick, N. Ashton, K. Lau, N. Hancock, et al. 1994. Characteriza-
tion of sequences within heparin-binding EGF-like growth factor that medi-
ate interaction with heparin. J. Biol. Chem. 269:2541Ð2549.
Thorne, B.A., and G.D. Plowman. 1994. The heparin-binding domain of amphi-
regulin necessitates the precursor pro-region for growth factor secretion.
Mol. Cell. Biol. 14:1635Ð1646.
Threadgill, D.W., A.A. Dlugosz, L.A. Hansen, T. Tennenbaum, U. Lichti, D.
Yee, C. LaMantia, T. Mourton, K. Herrup, R.C. Harris, et al. 1995. Targeted
disruption of mouse EGF receptor: effect of genetic background on mutant
phenotype. Science. 269:230Ð234.
Toyoda, H., T. Komurasaki, Y. Ikeda, M. Yoshimoto, and S. Morimoto. 1995.
Molecular cloning of mouse epiregulin, a novel epidermal growth factor-
related protein, expressed in the early stage of development. FEBS Lett. 377:
403Ð407.
Traverse, S., K. Seedorf, H. Paterson, C.J. Marshall, P. Cohen, and A. Ullrich.
1994. EGF triggers neuronal differentiation of PC12 cells that overexpress
the EGF receptor. Curr. Biol. 4:694Ð701.
Tzahar, E., R. Pinkas-Kramarski, J.D. Moyer, L.N. Klapper, I. Alroy, G.
Levkowitz, M. Shelly, S. Henis, M. Eisenstein, B.J. Ratzkin, et al. 1997. Biva-
lence of EGF-like ligands drives the ErbB signaling network. EMBO (Eur.
Mol. Biol. Organ.) J. 16:4938Ð4950.
Upton, C., J.L. Macen, and G. McFadden. 1987. Mapping and sequencing of a
gene from myxoma virus that is related to those encoding epidermal growth
factor and transforming growth factor alpha. J. Virol. 61:1271Ð1275.
Wiley, H.S. 1985. Receptors as models for the mechanisms of membrane pro-
tein turnover and dynamics. Curr. Top. Membr. Transp. 24:369Ð412.
Wiley, H.S. 1988. Anomalous binding of epidermal growth factor to A431 cells
is due to the effect of high receptor densities and a saturable endocytic sys-
tem. J. Cell Biol. 107:801Ð810.
Winkler, M.E., L. OÕConnor, M. Winget, and B. Fendly. 1989. Epidermal
growth factor and transforming growth factor alpha bind differently to the
epidermal growth factor receptor. Biochemistry. 28:6373Ð6378.
Wong, S.T., L.F. Winchell, B.K. McCune, H.S. Earp, J. Teixido, J. Massagu, B.
Herman, and D.C. Lee. 1989. The TGF-alpha precursor expressed on the
cell surface binds to the EGF receptor on adjacent cells, leading to signal
transduction. Cell. 56:495Ð506.
Xie, W., A.J. Paterson, E. Chin, L.M. Nabell, and J.E. Kudlow. 1997. Targeted
expression of a dominant negative epidermal growth factor receptor in the
mammary gland of transgenic mice inhibits pubertal mammary duct devel-
opment. Mol. Endocrinol. 11:1766Ð1781.
Yoshitake, Y., and K. Nishikawa. 1988. Production of monoclonal antibodies
with specificity for different epitopes on the human epidermal growth factor
molecule. Arch. Biochem. Biophys. 263:437Ð446.